Septerna, Inc. (NASDAQ:SEPN) Given Average Recommendation of “Moderate Buy” by Brokerages

Septerna, Inc. (NASDAQ:SEPN) has received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $26.75.

Several research analysts have issued reports on SEPN shares. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Septerna in a report on Thursday, August 21st. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of Septerna in a report on Friday, September 5th. Finally, Wall Street Zen lowered shares of Septerna from a “hold” rating to a “sell” rating in a report on Saturday.

Septerna Price Performance

Septerna stock opened at $14.44 on Wednesday. The business has a 50 day moving average of $12.60 and a 200-day moving average of $9.55. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99. The company has a market capitalization of $643.74 million and a P/E ratio of -1.43.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Equities analysts anticipate that Septerna will post -7.11 EPS for the current year.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rangeley Capital LLC boosted its holdings in shares of Septerna by 10.7% during the 2nd quarter. Rangeley Capital LLC now owns 58,605 shares of the company’s stock worth $619,000 after buying an additional 5,655 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Septerna during the 2nd quarter worth approximately $5,723,000. Boothbay Fund Management LLC bought a new position in shares of Septerna during the 2nd quarter worth approximately $255,000. Bank of America Corp DE boosted its holdings in shares of Septerna by 758.3% during the 2nd quarter. Bank of America Corp DE now owns 99,213 shares of the company’s stock worth $1,049,000 after buying an additional 87,654 shares in the last quarter. Finally, VR Adviser LLC bought a new position in shares of Septerna during the 2nd quarter worth approximately $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.